40 results
8-K
EX-99.2
ANNX
Annexon Inc
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
Analysis of Neurofilament Light Chain (NfL) Assessment of reduction of neuronal damage Change in Serum NfL Weeks 2 - 4 p=0.03 Key Takeaways p=0.027 … Placebo (n=77) 30 mg/kg (n=76) Prespecified assessment of NfL reduction 75 mg/kg (n=77) during weeks 2‐ 4 consistent with Ph1b Captures transition from
8-K
EX-99.1
ANNX
Annexon Inc
13 May 24
Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
4:05pm
assessment of photoreceptor function in low light conditions.
▪Statistically significant reduction of photoreceptor loss as measured by assessment
8-K
EX-99.1
ANNX
Annexon Inc
7 May 24
Other Events
4:05pm
Ellipsoid Zone assessment, a direct measure of photoreceptor anatomy
Greater slowing of RPE loss in patients with baseline foveal involvement compared … to overall population (Fundus Autofluorescence Photography Assessment)
50% reduction in the number of patients with substantial RPE loss in the fovea
424B5
kcmb3zz6e
21 Dec 23
Prospectus supplement for primary offering
4:05pm
8-K
EX-99.3
dv2632i0sjj9kmppm
20 Dec 23
Regulation FD Disclosure
5:17pm
424B3
lsqc q6ums8r6b
16 Nov 22
Prospectus supplement
4:26pm
S-3
kkhpi46b
4 Nov 22
Shelf registration
4:47pm
POS AM
li92ur00ba3oe18
1 Mar 22
Prospectus update (post-effective amendment)
6:38pm